Tofacitinib in pyoderma gangrenosum - A case series

Pyoderma gangrenosum (PG) is a rare autoinflammatory disorder falling under the spectrum of neutrophilic dermatosis, characterized by distinctive skin ulceration which is non-infective, non-neoplastic and usually with no primary vasculitis. PG lesions are notorious for relapse and hence require multiple trials of medications often with prolonged and concomitant use of steroids. Due to lack of evidence-based studies on effective treatment options for PG, we have presented three isolated biopsy-proven PG cases who were successfully treated with Tofacitinib, a Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway inhibitor, without relapse in follow up.

Automated summary

Pyoderma gangrenosum (PG) is a rare autoinflammatory disorder characterized by distinctive non-infective, non-neoplastic skin ulceration. Effective treatment options for PG are lacking, but we have presented three cases successfully treated with Tofacitinib, a JAK/STAT pathway inhibitor, without relapse in follow up.